NCT07260708 2025-12-19
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
Clinical Trials
33 trialsNCT01375114 2025-10-28
The Effects of Ginseng on Cancer-Related Fatigue
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06649656 2024-10-21
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06413953 2024-07-03
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT03375983 2024-02-20
Plasmodium Immunotherapy for Advanced Cancers
CAS Lamvac Biotech Co., Ltd.
Phase 1/2 Recruiting
NCT05333276 2023-07-27
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT01430572 2023-06-06
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02042989 2022-07-11
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05380882 2022-05-19
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT02272595 2022-02-15
Rational Therapeutics Based on Matched Tumor and Normal Tissue
M.D. Anderson Cancer Center
Completed
NCT02561234 2021-11-05
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Aeglea Biotherapeutics
Phase 1/2 Completed
NCT01548144 2021-09-13
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02558257 2021-04-14
Perception of Palliative Care Encounter
M.D. Anderson Cancer Center
Completed
NCT01021072 2021-02-16
A First in Man Study of MABp1 in Patients With Advanced Cancers
Janssen Research & Development, LLC
Phase 1 Completed
NCT02597478 2021-02-09
Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02508662 2020-07-14
Registry Study for Personalized Cancer Therapy
M.D. Anderson Cancer Center
Completed
NCT02521194 2020-01-13
Occupational Therapy in Palliative Care
M.D. Anderson Cancer Center
Phase NA Terminated
NCT02160366 2020-01-10
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
M.D. Anderson Cancer Center
Unknown
NCT02498899 2019-03-19
Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion
M.D. Anderson Cancer Center
Phase NA Completed
NCT01213238 2019-03-15
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00836927 2019-02-18
MK-8669-038
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01532011 2016-07-04
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01454804 2016-04-13
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00941499 2015-11-18
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00895362 2015-07-13
Erlotinib in Combination With Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02193672 2014-07-18
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01200004 2013-08-02
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01432119 2013-04-09
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00473720 2013-01-23
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Yale University
Phase 1 Completed
NCT01608139 2012-10-19
Study of Curcumin, Vorinostat, and Sorafenib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00496444 2012-08-01
Azacytidine and Valproic Acid in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00499382 2012-08-01
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
M.D. Anderson Cancer Center
Terminated
NCT00903708 2012-07-30
LY2275796 in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed